IL149924A0 - Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases - Google Patents
Vaccine for the prevention and treatment of alzheimer's and amyloid related diseasesInfo
- Publication number
- IL149924A0 IL149924A0 IL14992400A IL14992400A IL149924A0 IL 149924 A0 IL149924 A0 IL 149924A0 IL 14992400 A IL14992400 A IL 14992400A IL 14992400 A IL14992400 A IL 14992400A IL 149924 A0 IL149924 A0 IL 149924A0
- Authority
- IL
- Israel
- Prior art keywords
- alzheimer
- vaccine
- prevention
- treatment
- related diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16859499P | 1999-11-29 | 1999-11-29 | |
US72484200A | 2000-11-28 | 2000-11-28 | |
PCT/CA2000/001413 WO2001039796A2 (en) | 1999-11-29 | 2000-11-29 | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL149924A0 true IL149924A0 (en) | 2002-11-10 |
Family
ID=26864284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14992400A IL149924A0 (en) | 1999-11-29 | 2000-11-29 | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1235587A2 (xx) |
JP (1) | JP2004500354A (xx) |
KR (2) | KR20080059676A (xx) |
CN (1) | CN1433321A (xx) |
AU (1) | AU784312B2 (xx) |
BR (1) | BR0016022A (xx) |
CA (1) | CA2388559A1 (xx) |
HK (1) | HK1049279A1 (xx) |
IL (1) | IL149924A0 (xx) |
MX (1) | MXPA02005576A (xx) |
NO (1) | NO20022531L (xx) |
NZ (1) | NZ540564A (xx) |
WO (1) | WO2001039796A2 (xx) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1072897A (en) | 1995-12-12 | 1997-07-03 | Karolinska Innovations Ab | Peptide binding the klvff-sequence of amyloid beta |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
MXPA02007796A (es) * | 2000-02-21 | 2003-12-08 | Pharmexa As | Metodo novedoso para la disminucion de cuerpos amiloides. |
CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
AU2007200047B2 (en) * | 2000-07-07 | 2009-11-26 | Bioarctic Neuroscience Ab | Prevention and treatment of Alzheimer's disease |
US20020115717A1 (en) * | 2000-07-25 | 2002-08-22 | Francine Gervais | Amyloid targeting imaging agents and uses thereof |
US7311893B2 (en) | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
JP2006511452A (ja) * | 2002-07-03 | 2006-04-06 | バイオ サイエンス インターナショナル インコーポレイテッド | 芳香族d−アミノ酸を含むペプチドおよびその利用方法 |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
EP1658264A2 (en) * | 2003-06-23 | 2006-05-24 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
EP1699810A4 (en) * | 2003-12-17 | 2009-10-21 | Elan Pharm Inc | BETWEEN BETA IMMUNOGENIC PEPTIDE CONJUGATES PRODUCTION TECHNIQUES OF THESE CONJUGATES |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
EP1838348B1 (en) | 2004-12-15 | 2013-06-26 | Janssen Alzheimer Immunotherapy | Humanized amyloid beta antibodies for use in improving cognition |
JP5145537B2 (ja) | 2004-12-22 | 2013-02-20 | ビーエイチアイ リミテッド パートナーシップ | アミロイド関連疾患を治療するための方法および組成物 |
KR100851035B1 (ko) | 2005-08-23 | 2008-08-11 | 대한민국 | GCP-Ⅱ를 유효성분으로 함유하는 β-아밀로이드의 뇌내축적 예방 및 치료용 약학적 조성물과 치료제 스크리닝용조성물 및 이를 이용한 스크리닝 방법 |
KR20080095836A (ko) | 2005-11-10 | 2008-10-29 | 로스캄프 리서치 엘엘씨 | A―베타 펩티드 단편에 의한 혈관형성의 조정 |
KR101434935B1 (ko) | 2005-11-30 | 2014-10-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의용도 |
JP5475994B2 (ja) | 2005-11-30 | 2014-04-16 | アッヴィ・インコーポレイテッド | 抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。 |
ES2407429T3 (es) * | 2005-12-12 | 2013-06-12 | Ac Immune S.A. | Vacuna terapéurica |
UY30003A1 (es) | 2005-12-12 | 2007-08-31 | Hoffmann La Roche | Anticuerpos glicosilados en la region variable |
NO347079B1 (no) | 2006-03-23 | 2023-05-08 | Bioarctic Neuroscience Ab | Forbedrede protofibrilselektive antistoffer og anvendelse derav |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2008060364A2 (en) * | 2006-10-02 | 2008-05-22 | Ac Immune S.A | Humani zed antibody against amyloid beta |
KR101605207B1 (ko) | 2006-07-14 | 2016-03-22 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
KR20160147066A (ko) * | 2006-07-14 | 2016-12-21 | 에이씨 이뮨 에스.에이. | 아밀로이드 베타에 대해 인간화된 항체 |
SG175603A1 (en) * | 2006-10-12 | 2011-11-28 | Bellus Health International Ltd | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JP5349297B2 (ja) | 2007-04-20 | 2013-11-20 | 一般財団法人化学及血清療法研究所 | ペプチド免疫応答増強方法 |
JP2010528583A (ja) * | 2007-06-11 | 2010-08-26 | エーシー イミューン ソシエテ アノニム | アミロイドβに対するヒト化抗体 |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
PL2182983T3 (pl) | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
CN101883790B (zh) | 2007-10-05 | 2015-09-09 | 基因技术公司 | 抗淀粉样蛋白β抗体在眼病中的用途 |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
WO2009143489A2 (en) * | 2008-05-22 | 2009-11-26 | Archer Pharmaceuticals, Inc. | Modulation of angiogenesis by a-beta peptide fragments |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP2273273A1 (en) * | 2009-07-11 | 2011-01-12 | Rheinische Friedrich-Wilhelms-Universität Bonn | Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease |
CN104744591B (zh) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | β淀粉样蛋白结合蛋白 |
AU2011282536B2 (en) | 2010-07-30 | 2015-12-24 | Ac Immune S.A. | Safe and functional humanized anti beta-amyloid antibody |
CA2808187A1 (en) | 2010-08-14 | 2012-02-23 | Abbvie Inc. | Amyloid-beta binding proteins |
PL3166970T3 (pl) | 2014-07-10 | 2021-09-13 | Bioarctic Ab | Ulepszone przeciwciała wiążące protofibryle a-beta |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
IL258317B1 (en) | 2015-10-02 | 2024-08-01 | Hoffmann La Roche | Human anti–CD20/human transferrin receptor bispecific antibodies and methods of use |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
KR20180094876A (ko) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
AU2016354688B2 (en) | 2015-11-09 | 2021-12-16 | The University Of British Columbia | Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto |
CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001500852A (ja) * | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | D―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
JP2003503312A (ja) * | 1999-05-05 | 2003-01-28 | ニューロシェム インコーポレイテッド | 立体選択的抗原線維形成ペプチドおよびそのペプチド模倣体 |
-
2000
- 2000-11-29 MX MXPA02005576A patent/MXPA02005576A/es not_active Application Discontinuation
- 2000-11-29 EP EP00981111A patent/EP1235587A2/en not_active Withdrawn
- 2000-11-29 JP JP2001541528A patent/JP2004500354A/ja active Pending
- 2000-11-29 CN CN00816414A patent/CN1433321A/zh active Pending
- 2000-11-29 NZ NZ540564A patent/NZ540564A/en unknown
- 2000-11-29 WO PCT/CA2000/001413 patent/WO2001039796A2/en active Application Filing
- 2000-11-29 AU AU18473/01A patent/AU784312B2/en not_active Ceased
- 2000-11-29 BR BR0016022-9A patent/BR0016022A/pt not_active Application Discontinuation
- 2000-11-29 CA CA002388559A patent/CA2388559A1/en not_active Abandoned
- 2000-11-29 IL IL14992400A patent/IL149924A0/xx unknown
- 2000-11-29 KR KR1020087013848A patent/KR20080059676A/ko not_active Application Discontinuation
- 2000-11-29 KR KR1020027006845A patent/KR20020073341A/ko not_active Application Discontinuation
-
2002
- 2002-05-28 NO NO20022531A patent/NO20022531L/no not_active Application Discontinuation
-
2003
- 2003-01-16 HK HK03100407.4A patent/HK1049279A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU1847301A (en) | 2001-06-12 |
EP1235587A2 (en) | 2002-09-04 |
NZ540564A (en) | 2007-04-27 |
WO2001039796A3 (en) | 2001-12-06 |
BR0016022A (pt) | 2002-08-06 |
NO20022531L (no) | 2002-07-12 |
KR20080059676A (ko) | 2008-06-30 |
AU784312B2 (en) | 2006-03-09 |
CA2388559A1 (en) | 2001-06-07 |
JP2004500354A (ja) | 2004-01-08 |
HK1049279A1 (zh) | 2003-05-09 |
MXPA02005576A (es) | 2002-12-13 |
WO2001039796A2 (en) | 2001-06-07 |
KR20020073341A (ko) | 2002-09-23 |
NO20022531D0 (no) | 2002-05-28 |
CN1433321A (zh) | 2003-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL149924A0 (en) | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases | |
HUP0103654A2 (hu) | Szmilagenin és/vagy anzurogenin-D alkalmazása Alzheimer-kór kezelésére szolgáló gyógyszerkészítmény előállítására | |
SI1303272T1 (sl) | Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni | |
AU2001249835A1 (en) | Diagnosis and treatment of alzheimer's disease | |
GB2368794B (en) | Prevention and treatment of amyloidogenic disease | |
HUP0201205A3 (en) | Prevention and treatment of amyloidogenic disease | |
HUP0003852A3 (en) | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias | |
AU2002335794A1 (en) | Allylamides useful in the treatment of alzheimer's disease | |
NO20001869D0 (no) | Fremgangsmõte for behandling av Alzheimerssykdom | |
AU2002212471A1 (en) | Peptides for use in the treatment of alzheimer's disease | |
AU3840802A (en) | Methods and compositions for the treatment of diseases of the eye | |
HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
AU2002222108A1 (en) | Diagnosis and treatment of alzheimer's disease | |
IL117695A0 (en) | Pharmaceutical agents for the treatment of alzheimer's disease | |
GB0011410D0 (en) | Therapeutic combination for treating Alzheimer's disease | |
AU2003248660A8 (en) | Treatment of vascular dysfunction and alzheimer's disease | |
AU5550800A (en) | Diagnosis and treatment of alzheimer's disease | |
GB0011430D0 (en) | Acombination of therapeutic agents for treating Alzheimer's Disease | |
GB0011408D0 (en) | Therapeutic combination for treating Alzheimer's Disease | |
EP1181550A4 (en) | METHODS OF IDENTIFYING COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
PL377110A1 (pl) | Zapobieganie i leczenie choroby Alzheimera | |
IL153439A0 (en) | Medicines for the prevention and treatment of neurodegenerative diseases | |
HUP0103149A3 (en) | Pharmaceutical composition for treatment of alzheimer's disease | |
AU2002319451A1 (en) | Therapeutic strategies for prevention and treatment of alzheimer's disease | |
HUP0301847A3 (en) | Use of adatanserin for producing pharmaceutical compositions for the treatment and prevention of neurodegenerative conditions |